<DOC>
	<DOCNO>NCT02834611</DOCNO>
	<brief_summary>This study dose escalation study Ceramide NanoLiposome patient advance solid tumor .</brief_summary>
	<brief_title>Ceramide NanoLiposome Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Signed informed consent/authorization obtain prior conduct studyspecific screening procedure . 18 year age order Histologic cytologic diagnosis cancer Patients without curative therapy whose tumor standard chemotherapy At least 4 week last dose chemotherapy radiation therapy ; 6 week mitoxantrone mitomycin therapy Eastern Cooperative Oncology Group ( ECOG ) performance status must ≤2 ( Appendix A ) . Adequate hepatic , renal , bone marrow function : Absolute neutrophil count ≥ 1,000/microliter ( uL ) Platelets ≥ 100,000/uL Total bilirubin ≤2.0 AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 X institutional ULN Creatinine ≤1.2 mg/dL clearance ≥50ml/min ( CockcroftGault ) All participant ( male female ) reproductive potential must practice effective method contraception study order minimize risk fetus . Radiographic evidence measurable disease tumor lesion ( ≥ 1cm great dimension ) nodal disease ( &gt; 1.5cm great dimension ) Men woman ethnic group eligible trial . Females reproductive age must negative urine pregnancy test prior entry study Life expectancy great 12 week . Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia well control medication , myocardial infarction within previous 6 month , psychiatric illness/social situation would limit compliance study requirement . Patients may receive concurrent investigational agent , receive investigational agent within four week commence protocol . Since teratogenic potential combination currently unknown , female pregnant lactate exclude . Males female perform abstinence use barrier prevent pregnancy . History malignancy last 2 year except insitu cancer , nonmuscle invasive bladder cancer , basal squamous cell skin cancer eligible Patients know HIV ( + ) , Hep BsAg ( + ) , Hep C ( + ) exclude effect agent immune system assess Patients history hypersensitivity liposomal product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>